ibandronic acid

EUEMA:by INNUSDailyMed:Ibandronate_sodiumUSFDA:Ibandronate_sodium AU:B3 M05BA06(WHO) US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate 114084-78-5Y 60852 3059 DB00710N 54839Y UMD7G2653W D08056Yas salt:D04486Y CHEBI:93770 ChEMBL997Y BFQ (PDBe,RCSB PDB) DTXSID5048340 Interactive image O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)YKey:MPBVHIBUJCELCL-UHFFFAOYSA-NY Ibandronic acidis abisphosphonatemedication used in the prevention and treatment ofosteoporosisand metastasis-associated skeletal fractures in people with cancer.It may also be used to treathypercalcemia(elevated bloodcalciumlevels). It is typicallyformulatedas itssodiumsaltibandronate sodium. Ibandronate, or ibandronic acid, is primarily used to prevent and treat postmenopausal osteoporosis in women.Its U.S. brand name is Boniva,and in contrast to most other bisphosphonate drugs, Ibandronate can be administered both orally and intravenously. It was patented in 1986 byBoehringer Mannheimand approved for medical use in 1996.